Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
· Circio´s position as a pioneering player in the rapidly emerging circular RNA field is being recognized in the industry · Five articles and interviews have recently been published in widely read EU and US life science publications with a combined readership of over 3 million · Additional high-profile interviews are expected to generate further coverage in the coming monthsOslo, Norway, 25 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has initiated a systematic